Growth hormone axis
Ipamorelin
Editorial audit: October 15, 2026 · draft; scientific, medical and translation review pending
01What is reported
Ipamorelin appears in community GH-secretagogue combinations. Some sources present cycling and timing as established principles without direct comparisons.
02Proposed rationale
The proposed rationale is stimulation of GH release. A hormonal response and a meaningful clinical outcome are separate questions.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
03What the research shows
A controlled postoperative intravenous study did not demonstrate significance for its key meal-tolerance endpoint. Its population, route and purpose differ from community recovery use.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
04Limits and unknowns
A negative result in that indication does not prove universal inactivity. It also does not validate subcutaneous performance stacks. One source contains an apparent dose-unit error that must not be silently corrected.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
05Questions to ask about the product
Identify formulation and route, and check the source document for an erratum before reusing any ambiguous number.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
06Open research question
What proportion of recorded community claims can be traced to a study with the same intervention and outcome?
Primary and regulatory references
- 1.
- 2.